| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 157 | 2020 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood, The Journal of the American Society of Hematology 141 (13), 1610-1625, 2023 | 60 | 2023 |
| Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax A Waclawiczek, AM Leppä, S Renders, K Stumpf, C Reyneri, B Betz, ... Cancer Discovery 13 (6), 1408-1427, 2023 | 55 | 2023 |
| Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types MM Majumder, AM Leppä, M Hellesøy, P Dowling, A Malyutina, ... haematologica 105 (6), 1527, 2020 | 23 | 2020 |
| Frequent whole blood donations select for DNMT3A variants mediating enhanced response to erythropoietin. D Karpova, HH Encabo, E Donato, I Kotova, S Calderazzo, AM Leppae, ... medRxiv, 2022 | 2 | 2022 |
| An arms‐race against resistance: leukemic stem cells and lineage plasticity A Waclawiczek, AM Leppä, S Renders, A Trumpp Molecular Oncology, 2024 | 1 | 2024 |
| Opsonization-independent antigen-specific recognition by myeloid phagocytes expressing monoclonal antibodies M Neumaier, S Giesler, V Ast, M Roemer, TD Voß, E Reinz, V Costina, ... Science Advances 9 (35), eadg1812, 2023 | 1 | 2023 |
| Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition S Renders, AM Leppä, A Waclawiczek, M Janssen, E Donato, C Reyneri, ... Blood 138 (Supplement 1), 3469-3469, 2021 | 1 | 2021 |
| A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines R Silvennoinen, MM Majumder, D Tsallos, H Nahi, P Anttila, A Partanen, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e279-e280, 2019 | 1 | 2019 |
| A High-Throughput Biology Approach to Identify Novel Therapies Specifically Targeting AML Blasts and Leukemic Stem Cells H Kuusanmäki, AM Leppä, D Deb, CA Heckman Blood 128 (22), 2755, 2016 | 1 | 2016 |
| PS973 BCL-XL AS A PUTATIVE THERAPY TARGET IN ACUTE ERYTHROID LEUKEMIA H Kuusanmäki, O Dufva, AM Leppä, P Pölönen, M Heinäniemi, K Porkka, ... HemaSphere 3 (S1), 438-439, 2019 | | 2019 |
| Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies MM Majumder, AM Leppä, CA Heckman Blood 128 (22), 3515, 2016 | | 2016 |
